Organ-on-a-Chip Resources

Organ-on-a-chip Contract Research Services Brochure

Discover our full range of Organ-on-a-chip contract research services including ADME, NASH, DILI and Oncology as well as all the relevant endpoints.

A primary jejunum and primary hepatocyte multi-organ MPS

Find out how our gut-liver MPS recapitulates the physiological condition enabling oral drug dosing in vitro. This gut-liver model offers a vast improvement in the methods used to study PK or prodrugs.

ADME Studies: Determining Promising Drug Compounds

Dr Abbas discusses factors that can affect the outcome of an ADME study, signs that a drug compound shows promise, red flags, and key parameters to determine safety and efficacy.

This article is taken from PharmTech, November 2022.

How to Keep Breathing – The Future of Inhaled Medication Testing

Dr Emily Richardson discusses the current challenges faced to bring inhaled therapeutics to the market and the potential of Organ-on-a-Chip to increase positive outcome by improving ADME drug testing.

This article is taken from International Biopharmaceutical Industry, Summer 2022.

PhysioMimix Multi-organ System Animation

An introduction to the CN Bio PhysioMimix Multi-organ System. This animation demonstrates how our microphysiological system works, how to create a Gut/Liver-on-a-chip model and an example of its use.

Why two organs are better than one

Abbas, Kostrzewski & Hughes

This poster demonstrates how a gut-liver MPS can improve oral bioavailability predictions by mimicking human oral and IV regimens. Thus improving the in vitro to in vivo translation of drug efficacy and safety.

Predicting Drug Bioavailability with the Modern-Day Toolkit

Animal models continue to be used in bioavailability research but limitations are serious and difficult to overcome. Find out how OOC can help solve your PK/PD and bioavailability issues.

This article is taken from International Biopharmaceutical Industry Winter 2021, pages 14-17.

Improved prediction of oral bioavailability using a gut-liver microphysiological system

Abbas, Kostrzewski & Hughes

Central to the development of new drugs is an understanding of their pharmacokinetic properties, in particular their bioavailability. Here, we demonstrate the potential of a true 2-organ gut-liver MPS to better predict human bioavailability and improve in vitro to in vivo correlation.

From Dose to Circulation: Determination of Drug Oral Bioavailability Using a Gut-Liver Microphysiological System

Webinar Series 4 Episode 4

In this webinar, Dr. Yassen Abbas discusses how CNBio’s gut-liver MPS can be used for in vitro determination of oral bioavailability. This application has been validated with drugs with known human bioavailability and with a mathematical model developed to enable prediction of oral bioavailability in silico.

Microphysiological systems of the human liver, gut and linked liver-gut, to assess human drug absorption, metabolism and bioavailbility

Kostrzewski et al

This poster demonstrates the potential of human MPS models for liver, gut, and multi-organ (connecting gut with liver) for the investigation of human PK parameters, drug absorption and metabolism, and bioavailability.

Towards a Body-on-a-Chip: The Value of Multi-Organ MPS for Human-Relevant Drug Assessment

Webinar Series 3 Episode 1:

In this webinar, Dr Tomasz Kostrzewski, VP – Science & Technology explores how single-and multi-organ MPS can be incorporated into your drug discovery and development workflows to increase in vitro to in vivo translation of preclinical assays.

Gut-liver organ-on-a-chip combined with in silico modeling as a promising tool for investigation of mycophenolate mofetil pharmocokinetics

Milano et al

This poster demonstrates the potential of a true 2-organ gut-liver MPS for ADME applications and is more relevant in vitro to in vivo translation of drug efficacy and toxicity.